OBJECTIVES: Utilizing previously published selection criteria, identify and evaluate current literature that is focused on cost-effectiveness of genotype-guided medication programs for patients at high risk for a thrombotic event.  The aim of study is to provide the scientific community with a comprehensive, yet brief overview of studies that could inform future development of personalized medicine research within this subset of cardiovascular disease. METHODS: The literature search was conducted within PubMed and Web of Science databases. The objective was to identify studies published from January 2008 (conclusion period of Vegtar's research) to October 2014 that also included the search term “pharmacogenetic” and the term “pharmacoeconomic”.  RESULTS: Ten articles met inclusion criteria. Genotypes CYP2C19, CYP2C9, VKORC1, KIF6 were used alone and/or in combination within differing patient populations. Medication programs included (number of papers): Warfarin (4), Clopidgrel (including other in-class agents: 2), phenprocoumon (1), atorvastatin/pravastatin (1) and Dabigitran (and other in-class agents: 1). The following types of economic evaluations were utilized either alone or in combination: CEA, CUA, CUR, CBA, Threshold Analysis, ICER, ICUR, EA, and INB. Outcome measures and sensitivity analysis were variable and did not always reach thresholds of significance within the overall study population. CONCLUSIONS: Comprehensive study evaluations were lacking due to inconsistent methodology. Specific study guidelines for the field of genotype-guided therapy are needed. With mulitiple blockbuster medications reaching patent expiry, the cost-effectiveness and sensitivity analysis from previous years warrant a second evaluation. It is anticipated that genotype-guided treatment may be shifting to a cost-effective option for only the treatment-resistant, or smaller populations with a differentiated risk status. This is in contrast to selecting genotype-driven therapy as an initial option for the masses of patients diagnosed with thrombotic event risk in a more traditional “treat everyone the same” algorithim. Stepfan Vegter et. al, "Pharmacoeconomic Evaluations of Pharmacogenetic and Genomic Screening Programmes" Pharmacoeconomics 2008: 26(7) 569-587.